Abstract: Methods are provided for the large-scale high-content analysis of biological samples. In some embodiments, the methods are implemented in a reversed open microwell system that includes an array of open microwells, at least one microchannel, at least one input port and at least one output port. In certain embodiments, the reversed open microwell system can be inserted in an automated management system which includes an incubator at controlled temperature, humidity and CO2 levels, a fluid dispensing system, and is capable of phase-contrast and fluorescence image acquisition. Also provided are kits for introducing fluids into a microfluidic device, and systems for discharging one or more fluids in a microfluidic device.

Abstract: Systems, methods, and devices for selective capture and release of target particles, e.g., living cells, from liquid samples, e.g., blood, are provided. The particle capture systems include a substrate; a first layer of gelatin bound to the substrate by physical adsorption, wherein the gelatin is functionalized with a plurality of first members of a binding pair; a second layer of gelatin wherein the gelatin is functionalized with a plurality of the first members of the binding pair and the second layer is bound to the first layer via a plurality of second members of the binding pair that are associated with the first members of the binding pair on both the first and the second layers; and a plurality of nanostructures bound to the second members of the binding pair and to one or more particle-binding moieties that selectively bind to the target particles.

Abstract: The present invention provides a method for the assay of synucleins in a body fluid or tissue sample, wherein said method comprises the steps of contacting said sample with membrane lipids under conditions enabling binding of the synuclein to said lipids, and the detection of the lipid-bound synuclein by a synuclein-binding agent.

Abstract: The present invention relates to a system for biodetection applications comprising two basic elements, a substrate with a functionalized surface and a nanoparticle, the system being capable of enhancing the plasmonic effect of the nanoparticle. The invention also relates to a biosensor incorporating such system, in addition to the method for detecting and quantifying a target analyte selected in a sample using such system. Finally, the invention relates to a device which can detect the enhanced optoplasmonic effect of the nanoparticles by means of the system of the invention or by combining the detection of such optoplasmonic effect with the analysis of the changes in the mechanical characteristics in the substrate.

Abstract: An enzyme detection device (1) for detecting the presence, in a sample, of an enzyme capable of modifying a provided substrate (10). The device (1) comprises a substrate which has a modification region (14) that is sensitive to modification by the enzyme from an unmodified state to a modified state. The device (1) further comprises a substrate recognition molecule (16) which binds the modification region (14) in either the modified or the unmodified state. The modification region 14 of the substrate is preferentially bound by the substrate recognition molecule (16) as compared with the enzyme when mixed. The device further comprises a detectable label (18) coupled to the substrate recognition molecule (17).

Abstract: The present invention provides means and methods for selectively detecting activated MALT1 in a sample. Moreover, the present invention provides a method for diagnosing diseases, which are characterized by an increased MALT1 activity. Finally, the present invention provides methods for identifying patients which are amenable to treatment with a therapeutic agent capable of inhibiting MALT1 activity.

Abstract: The methods described herein are based on the discovery that the plasma level of a panel of specific proteins differs between two subject populations: 1) subjects at risk for chronic obstructive pulmonary disease (“COPD”) but not manifesting clinical symptoms of COPD; and 2) subjects having very severe COPD. The difference in plasma levels is statistically significant for each protein. The identification of these proteins thus facilitates susceptibility detection, early disease detection, disease severity assessment, disease progression monitoring, and therapy efficacy monitoring.

Abstract: This document provides methods and materials for identifying individuals with protein tyrosine kinase associated disorders for responsiveness to a kinase inhibitor (e.g., imatinib or nilotinib). For example, methods and materials for using a chemi-immunochromatographic lateral flow strip for detection of BCR-ABL and drug resistance are provided.

Abstract: The present invention fitted in the medical-clinical sector, shows a method for monitoring the ingestion of gluten by measuring protein/gluten peptides present in fecal samples with antibodies against immunogenic peptides resistant to gastrointestinal digestion. The presence or absence of these immunogenic peptides is controlled by immunological assays based on antibodies reactive against immunogenic gluten peptides that are resistant to proteolysis. These assays may be quantitative techniques ELISAs, or qualitative as rapid immunochromatographic assays, immunoblots, etc. These measures may also be applied to verify compliance with the gluten-free diet, to improve diagnosis in cases of refractory or severe symptoms of celiac disease in which a gluten-free diet is supposedly being respected, or to clinical research on the effectiveness of enzymatic therapies related with prolamin detoxification.

Abstract: The present invention relates to a method for assaying soluble GPC3 protein in a test sample, comprising using two different antibodies binding to different epitopes present in the N-terminal region of GPC3 protein.

Abstract: Disclosed is a method for measuring cholesterol by using a cholesterol dependent cytolysin (CDC), which is a cholesterol binding protein, and an antibody specifically recognizing HDL-C or LDL-C. The method according to the present application is capable of rapidly measuring low density lipoproteins and high density lipoproteins at low cost, and thus can be effectively applied in various fields requiring the measurement of low density lipoproteins and high density lipoproteins.

Abstract: This document provides methods and materials involved in performing flow cytometry assay methods. For example, flow cytometry assay methods and kits are provided.

Abstract: The present disclosure relates to monoclonal anti-LINE-1 ORF2 protein endonuclease domain antibody, and fragments and derivatives that bind the LINE-1 ORF2 protein endonuclease domain and inhibit its activity.

Abstract: The present invention concerns the field of diagnostic biological markers. Specifically the invention relates to anti-BAG3 antibodies for use as biological markers for the diagnosis of a pathological state. Furthermore, the invention involves specific ELISA methods and kits, for detecting and evaluating, anti-BAG3 antibodies or BAG3/antibody complexes in a biological sample.

Abstract: Methods for preparing a sample for detection of an analyte of interest that is bound in vivo to a protein are provided. The method comprises providing a processing reagent comprising metaperiodate and contacting a sample suspected of comprising an analyte of interest associated with a protein with the processing reagent to form a mixture. The analyte of interest, if present in the sample (or mixture), is separated from its associated protein for detection of the analyte of interest. In one embodiment, the method is applied to samples for the detection of levels of vitamin D circulating in the blood. Samples are processed using the reagent disclosed herein to separate the analyte of interest, vitamin D or a metabolite thereof, from the vitamin D binding protein and/or albumin, for detection of the analyte separated from its binding protein(s).

Abstract: A method is taught for the accurate determination of the premature rupture of membranes (PROM), defined as spontaneous rupture of membranes before the onset of uterine contractions. More specifically, a lateral flow assay strip tests for at least two antigens to greatly limit or eliminate the possibility of false negatives. A built-in timer in the cassette holding the lateral flow assay further increases the accuracy of the test. A collection buffer vial with self-contained shipping and dropper caps and built-in stand is also taught.

Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Cathepsin B, Renin, Dipeptidyl Peptidase IV, Neprilysin, Beta-2-microglobulin, Carbonic anhydrase IX, and C-X-C motif chemokine 2 as diagnostic and prognostic biomarkers in renal injuries.

Abstract: The present invention relates to a combination product for detecting a target marker simply and with high sensitivity. More specifically, the present invention relates to a combination product for detecting a target marker in a biological sample in combination with a target marker binding molecule which is capable of binding specifically to the target marker in the biological sample, the combination comprising, at least: (a) a first binding agent comprising a first binding molecule which is capable of directly or indirectly binding specifically to the target marker binding molecule, and a labeling substance; (b) a linker molecule which is capable of binding specifically to the first binding agent; and (c) a second binding agent which is capable of binding specifically to the linker molecule, and comprises a second binding molecule and a labeling substance.

Abstract: A method is disclosed for obtaining an antibody or antibody fragment to a conformational epitope specific for misfolded inactive human parathyroid hormone and fragments thereof. The method includes the steps of a) immunizing an animal with an immunogen which comprises oxidized parathyroid hormone or an oxidized fragment of parathyroid hormone, or both; and b) recovering an antibody, antibody fragments, or single chain antibody. The complementary determining region of the recovered antibody, antibody fragment or single chain antibody is capable of specifically recognizing a conformational epitope (antigenic determinant) which is present on oxidized parathyroid hormone and fragments thereof only but not regular bioactive human parathyroid hormone.

Abstract: A method of characterizing the protein O-GlcNAcylation site-specificity of an antibody. A method of detecting or quantitating the expression of site-specific O-GlcNAcylated proteins expressed in cells and biological samples. A method of diagnosing cancer in a host based on the cellular expression of site-specific O-GlcNAcylated proteins. A method of screening anti-cancer compounds according to their ability to increase a level O-GlcNAcylation of oncogene or tumor suppressor proteins. Methods of treating cancer in an animal host by administering compounds that increase a level of O-GlcNAcylated c-myc or p53 in cancer cells. A method of distinguishing subclasses of pancreatic cancer according to the sensitivity of pancreatic cancer cells to an imidazole derivative, and a method of personalized pancreatic cancer treatment delivered according to the sensitivity subclasses.